
This mouse strain (including any and all progeny, "MICE") is distributed by The Jackson Laboratory with the following terms and conditions.

Limited Use License for Mouse Models Generated with the CRISPR/Cas9 Technology.

This mouse strain or other product (the "Licensed Product") is sold by The Jackson Laboratory ("Jackson") under a license agreement with the Broad Institute, Inc. ("Broad") that contains certain limitations and obligations. By purchasing this product, you (the "Limited Licensee") agree to be bound by the following limited license (the "Limited License"). Additional capitalized terms are defined below.

Limited Licensee is granted the non-transferable right to use the Licensed Product and Enabled Products purchased from Jackson solely for research conducted by such Limited Licensee in accordance with all of the following requirements: (i) the Limited Licensee shall not sell or otherwise transfer the Licensed Product or Enabled Products (including without limitation any material that contains the Licensed Product or Enabled Products in whole or part) to any other person or entity or use the Licensed Product or Enabled Products to perform services for the benefit of any other person or entity other than bona fide research collaborators or contract research organizations, (ii) the Limited Licensee shall use only the purchased amount of the Licensed Product and components of the Licensed Product and Enabled Products, only for its internal research within the Field and not for any Commercial Purposes, however the Limited License will not prevent breeding of the Licensed Product for use under the Limited License, (iii) the Limited Licensee shall use the Licensed Product and Enabled Products in compliance with all applicable laws and regulations, including without limitation applicable human health and animal welfare laws and regulations, (iv) Jackson, Broad, The Massachusetts Institute of Technology ("MIT") and the President and Fellows of Harvard College ("Harvard") provide no warranties of any kind to the Limited Licensee (statutory or implied) concerning the Patent Rights, the Licensed Product or Enabled Products, including without limitation, as to product quality, condition, description, merchantability, fitness for a particular purpose, noninfringement of intellectual property rights or the absence of latent or other defects, and all such warranties are hereby expressly disclaimed, (v) Jackson, Broad, MIT and Harvard expressly disclaim any warranty regarding results obtained through the use of the Licensed Product or Enabled Products, including without limitation any claim of inaccurate, invalid or incomplete results, (vi) Jackson, Broad, MIT and Harvard, and their current and former directors, trustees, officers, employees, agents, faculty, affiliated investigators, and students, and their respective successors, heirs and assigns (collectively, the "Indemnitees") shall have no liability to the Limited Licensee, including, without limitation, for any loss of use or profits, business interruption or any consequential, incidental, special or other indirect damages of any kind, regardless of how caused and regardless of whether an action in contract, tort, strict product liability or otherwise, (vii) the Limited Licensee shall indemnify, defend and hold harmless the Indemnitees against any liability, damage, loss, or expense (including without limitation reasonable attorneys' fees and expenses) incurred by or imposed upon any of the Indemnitees in connection with any claims, suits, investigations,

actions, demands or judgments arising out of or related to the exercise of any rights granted to the Limited Licensee under the Limited License or any breach of the Limited License by such Limited Licensee, provided, however, that the foregoing shall not apply to a Limited Licensee that is an academic, non-profit, or government entity or person, and such Limited Licensee instead agrees that it, and not the Indemnitees, shall be responsible for any liability, damage, loss or expense arising out of or related to the exercise of any rights grant to the Limited Licensee under the Limited License or any breach of the Limited License by the Limited Licensee, and (viii) the Licensed Product and its use may be the subject of one or more issued patents and/or pending patent applications owned by Jackson, Broad, MIT and Harvard and the purchase of the Licensed Product does not convey a license under any claims in the foregoing patents or patent applications directed to the Licensed Product or use, production or commercialization thereof, other than the right to use the Licensed Product under the Limited License set forth above or as otherwise agreed between the parties in writing.

Definitions:

"Commercial Purpose" means: (a) the practice, performance or provision of any method, process or service, or (b) the manufacture, sale, use, distribution, disposition or importing of any product, in each case (a) or (b) for consideration, e.g., a fee, or on any other commercial basis.

"Enabled Product" means: any product, that is not the Licensed Product, which is or incorporates (a) any progeny, modification or derivative of the Licensed Product, or (b) any cell, organism or animal made or modified through use of the Licensed Product, or any progeny, modification or derivative of such cell, organism or animal. For clarity, any product that is made, produced or derived by use of the technology of the Patent Rights, such as a protein or a peptide from a cell line shall be deemed an Enabled Product; provided, however, that the term "Enabled Product" shall not include any large or small molecule that (i) was identified or discovered through screening using technology covered by the Patent Rights and (ii) does not otherwise fall within the foregoing clauses (a) through (b).

"Field" means: use as a research tool for research purposes; provided, however, that notwithstanding the foregoing, the Field shall expressly exclude (a) any clinical use, including, without limitation, diagnostic and prognostic use, (b) any human, veterinary, livestock or agricultural use, or (c) the manufacture, distribution, importation, exportation, transportation, sale, offer for sale, marketing, promotion or other exploitation or use of, or as, a testing service, therapeutic or diagnostic for humans or animals.

"Patent Rights" means (a) any patents and patent applications listed on Appendix A, which shall be updated from time-time.; (b) any substitutions, divisions, continuations, reissues, renewals, re-examinations or extensions of any patents or patent applications of (a), any continuations-in-part of any patents or patent applications of (a) to the extent the claims are directed to subject matter specifically described in a patent or patent application set forth on Appendix A, and any application claiming priority to a provisional application set forth on Appendix A to the extent the claims are directed to subject matter specifically described in a provisional patent application set forth on Appendix A; (c) any letters patents and/or the equivalent issuing therefrom in any jurisdiction based on any of the foregoing, and (d) any foreign or international equivalents of any of the foregoing, including without limitation any applications filed under the Patent Cooperation Treaty.

Appendix A

CaseNumber	Broad Ref#	AppNumber	FileDate	AppTitle
44790.AA.2003	BI-2011/008.PA1	61/736,527	12-Dec-12	SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.BB.2003	BI-2011/008.PA2	61/748,427	2-Jan-13	SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE

				MANIPULATION
44790.00.2003	BI-2011/008.PA3	61/757,972	29-Jan-13	SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.01.2003	BI-2011/008.PA4	61/768,959	25-Feb-13	SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.02.2003	BI-2011/008.PA5	61/791,409	15-Mar-13	SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.03.2003	BI-2011/008.PA6	61/835,931	17-Jun-13	SYSTEMS METHODS AND COMPOSITION FOR SEQUENCE MANIPULATION
44790.07.2003	BI-2011/008.US1	14/105,035	12-Dec-13	CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.99.2003	BI-2011/008.WO1	PCT/US2013/0746 11	12-Dec-13	CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.80.2003	BI-2011/008.EP1	13812430	29-Sep-14	CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.80.2044	BI-2011/008A.EP1	13824232.6	2-May-14	CRISPR-CAS SYSTEMS AND METHODS FOR ALTERING EXPRESSION OF GENE PRODUCTS
44790.04.2003	BI-2011/008A.US1	61/842,322	2-Jul-13	CRISPR-CAS SYSTEMS AND METHODS FOR ALTERING EXPRESSION OF GENE PRODUCTS
44790.05.2003	BI-2011/008A.US2	14/054,414	15-Oct-13	CRISPR-CAS SYSTEMS AND METHODS FOR ALTERING EXPRESSION OF GENE PRODUCTS (USP 8,697,359, issued April 15, 2014)
44790.11.2003	BI-2011/008A.US3	14/183,429	18-Feb-14	CRISPR-CAS SYSTEMS AND METHODS FOR ALTERING EXPRESSION OF GENE PRODUCTS (USP 8,771,945, issued July 8, 2014)
44790.10.2003	BI-2011/008A.US4	14/183,486	18-Feb-14	CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION (USP 8,795,965, issued August 5, 2014)
44790.13.2003	BI-2011/008A.US5	14/256,912	18-Apr-14	CRISPR-CAS SYSTEMS AND METHODS FOR ALTERING EXPRESSION OF GENE PRODUCTS
44790.14.2003	BI-2011/008A.US6	14/497,627	26-Sep-14	CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.99.2044	BI-2011/008A.WO1	PCT/US2013/0747 43	12-Dec-13	CRISPR-CAS SYSTEMS AND METHODS FOR ALTERING EXPRESSION OF GENE PRODUCTS
44790.06.2003	BI-2011/008B.US1	14/105,031	12-Dec-13	CRISPR-CAS NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION IN EUKARYOTES
44790.08.2003	BI-2011/008B.US2	14/183,471	18-Feb-14	CRISPR-CAS NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION IN EUKARYOTES (USP 8,889,356 to be issued November 18, 2014)
44790.09.2003	BI-2011/008B.US3	14/258,458	22-Apr-14	CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.12.2003	BI-2011/008B.US4	14/259,420	23-Apr-14	CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION (USP 8,871,445, issued October 28, 2014)
44790.99.2045	BI-2011/008B.WO1	PCT/US2013/0747 90	12-Dec-13	CRISPR-CAS NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION IN EUKARYOTES
44790.00.2005	BI-2011/020.PA1	61/675,778	25-Jul-12	INDUCIBLE DNA BINDING PROTEINS

				AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF
44790.01.2005	BI-2011/020.PA2	61/721,283	1-Nov-12	INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF
44790.02.2005	BI-2011/020.PA3	61/736,465	12-Dec-12	INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF
44790.03.2005	BI-2011/020.PA4	61/794,458	15-Mar-13	INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF
44790.12.2022	BI-2011/020.PA5	61/835,973	17-Jun-13	INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF
44790.99.2005	BI-2011/020.WO1	PCT/US13/051418	21-Jul-13	INDUCIBLE DNA BINDING PROTEINS AND GENOME PERTURBATION TOOLS AND APPLICATIONS THEREOF
44790.11.2022	BI-2012/084.PA1	61/836,080	17-Jun-13	METHODS, SYSTEMS, AND APPARATUS FOR IDENTIFYING TARGET SEQUENCES FOR CAS ENZYMES OR CRISPR-CAS SYSTEMS FOR TARGET SEQUENCES AND CONVEYING RESULTS THEREOF
44790.00.2040	BI-2012/084A.US1	14/104,900	12-Dec-13	METHODS, SYSTEMS, AND APPARATUS FOR IDENTIFYING TARGET SEQUENCES FOR CAS ENZYMES OR CRISPR-CAS SYSTEMS FOR TARGET SEQUENCES AND CONVEYING RESULTS THEREOF
44790.99.2040	BI-2012/084A.WO1	PCT/US2013/074825	12-Dec-13	METHODS, SYSTEMS, AND APPARATUS FOR IDENTIFYING TARGET SEQUENCES FOR CAS ENZYMES OR CRISPR-CAS SYSTEMS FOR TARGET SEQUENCES AND CONVEYING RESULTS THEREOF
44790.99.2046	BI-2012/084B.WO1	PCT/US2013/074812	12-Dec-13	METHODS, MODELS, SYSTEMS, AND APPARATUS FOR IDENTIFYING TARGET SEQUENCES FOR CAS ENZYMES FOR CRISPR-CAS SYSTEMS FOR TARGET SEQUENCES AND CONVEYING RESULTS THEREOF
44790.00.2041	BI-2013/003.US1	14/104,837	12-Dec-13	DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS
44790.01.2041	BI-2013/003.US2	14/183,512	18-Feb-14	DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS
44790.02.2041	BI-2013/003.US3	14/481,339	9-Sep-14	DELIVERY, ENGINEERING, AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS
44790.99.2041	BI-2013/003.WO1	PCT/US2013/074667	12-Dec-13	DELIVERY, ENGINEERING, AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS
44790.00.2022	BI-2013/003/004.PA1	61/758,468	30-Jan-13	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.01.2022	BI-2013/003/004.PA2	61/769,046	25-Feb-13	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND

				COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.02.2022	BI-2013/003/004.PA3	61/802,174	15-Mar-13	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.03.2022	BI-2013/003/004.PA4	61/806,375	28-Mar-13	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.04.2022	BI-2013/003/004.PA5	61/814,263	20-Apr-13	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.05.2022	BI-2013/003/004.PA6	61/819,803	6-May-13	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.06.2022	BI-2013/003/004.PA7	61/828,130	28-May-13	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.10.2022	BI-2013/003D.PA1	61/836,123	17-Jun-13	DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND APPLICATIONS
44790.13.2022	BI-2013/003D.PA2	61/847,537	17-Jul-13	DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND APPLICATIONS
44790.14.2022	BI-2013/003D.PA3	61/862,355	5-Aug-13	DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND APPLICATIONS
44790.15.2022	BI-2013/003D.PA4	61/871,301	28-Aug-13	DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND APPLICATIONS
44790.16.2022	BI-2013/003D.PA5	61/915,383	12-Dec-13	OPTIMIZED CRISPR-CAS DOUBLE NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.99.2022	BI-2013/003D.WO1	PCT/US2014/041803	10-Jun-14	OPTIMIZED CRISPR-CAS DOUBLE NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.09.2022	BI-2013/004E.PA1	61/836,101	17-Jun-13	ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.00.2042	BI-2013/004E.US1	14/104,977	12-Dec-13	ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.01.2042	BI-2013/004E.US2	14/222,930	24-Mar-14	ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION (USP 8,865,406, issued October 21, 2014)
44790.02.2042	BI-2013/004E.US3	14/293,498	2-Jun-14	ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.03.2042	BI-2013/004E.US4	14/293,674	2-Jun-14	ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION (USP8,889,418, to be issued November 18, 2014)

44790.99.2042	BI-2013/004E.WO1	PCT/US2013/0746 91	12-Dec-13	ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.07.2022	BI-2013/004F.PA1	61/835,936	17-Jun-13	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
44790.00.2043	BI-2013/004F.US1	14/105,017	12-Dec-13	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
44790.01.2043	BI-2013/004F.US2	14/226,274	26-Mar-14	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
44790.99.2043	BI-2013/004F.WO1	PCT/US2013/0747 36	12-Dec-13	ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
44790.80.2047	BI-2013/004G.EP1	13818570.7	27-May-14	ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.80.2075	BI-2013/004G.EP2	14170383.5	28-May-14	ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.08.2022	BI-2013/004G.PA1	61/836,127	17-Jun-13	ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.00.2047	BI-2013/004G.US1	14/104,990	12-Dec-13	ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.01.2047	BI-2013/004G.US2	14/290,575	29-May-14	ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.99.2047	BI-2013/004G.WO1	PCT/US2013/0748 19	12-Dec-13	ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.00.2024	BI-2013/007.PA1	61/799,800	15-Mar-13	RECOMBINANT VIRUS AND PREPARATIONS THEREOF
44790.01.2024	BI-2013/007.US1	14/213,991	14-Mar-14	RECOMBINANT VIRUS AND PREPARATIONS THEREOF
44790.99.2024	BI-2013/007.WO1	PCT/US2014/3039 4	17-Mar-14	RECOMBINANT VIRUS AND PREPARATIONS THEREOF
44790.00.2034	BI-2013/066.PA1	61/862,468	5-Aug-13	DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND OPTIMIZED COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.01.2034	BI-2013/066.PA2	61/915,407	12-Dec-13	DELIVERY, ENGINEERING AND OPTIMIZATION OF TANDEM GUIDE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.02.2034	BI-2013/066.PA3	61/979,942	15-Apr-14	DELIVERY, ENGINEERING AND OPTIMIZATION OF TANDEM GUIDE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
44790.99.2034	BI-2013/066.WO1	PCT/US2014/0418 00	10-Jun-14	DELIVERY, ENGINEERING AND OPTIMIZATION OF TANDEM GUIDE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE

				MANIPULATION
44790.00.2035	BI-2013/073.PA1	61/960,777	25-Sep-13	FUNCTIONAL GENOMICS USING CRISPR-CAS SYSTEMS, COMPOSITIONS, METHODS, SCREENS AND APPLICATIONS THEREOF
44790.03.2035	BI-2013/073.PA2	61/995,636	15-Apr-14	FUNCTIONAL GENOMICS USING CRISPR-CAS SYSTEMS, COMPOSITIONS, METHODS, SCREENS AND APPLICATIONS THEREOF
44790.99.2035	BI-2013/073.WO1	PCT/US2014/041806	10-Jun-14	FUNCTIONAL GENOMICS USING CRISPR-CAS SYSTEMS, COMPOSITIONS, METHODS, SCREENS AND APPLICATIONS THEREOF
44790.01.2035	BI-2013/073/078.PA1	61/961,980	28-Oct-13	FUNCTIONAL GENOMICS USING CRISPR-CAS SYSTEMS, COMPOSITIONS, METHODS, SCREENS AND APPLICATIONS THEREOF
44790.00.2065	BI-2013/112.US1	14/463,253	19-Aug-14	FUNCTIONAL GENOMICS USING CRISPR-CAS SYSTEMS, COMPOSITIONS, METHODS, KNOCKOUT LIBRARIES AND APPLICATIONS THEREOF
44790.99.2065	BI-2013/112.WO1	PCT/US2013/074800	12-Dec-13	FUNCTIONAL GENOMICS USING CRISPR-CAS SYSTEMS, COMPOSITIONS, METHODS, KNOCKOUT LIBRARIES AND APPLICATIONS THEREOF
44790.02.2041	BI-2014/071	14/481,339	9-Sep-14	DELIVERY ENGINEERING, AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS